1
|
Kocabas GU, Yurekli BS, Simsir IY, Ozgur S, Aksit M, Bozkaya G. Assessment of osteoprotegerin and RANKL levels and several cardiovascular risk scoring systems in acromegaly. Hormones (Athens) 2024; 23:81-88. [PMID: 37981618 DOI: 10.1007/s42000-023-00509-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Accepted: 11/09/2023] [Indexed: 11/21/2023]
Abstract
PURPOSE The OPG/RANKL (osteoprotegerin/receptor activator of nuclear factor kappa-B) system, which plays a crucial role in bone metabolism, is also associated with vascular calcification. Acromegaly is characterized by excessive secretion of growth hormone and insulin-like growth factor, and studies have demonstrated an elevated risk of cardiovascular disease in individuals with acromegaly. In this study, our objective was to investigate the relationship between OPG/RANKL and various cardiovascular risk scoring systems. METHODS We recruited 44 consecutive acromegaly patients and 41 healthy controls with a similar age and gender distribution for this study. RESULTS While RANKL levels were significantly higher in the acromegaly group compared to the controls, OPG levels were not found to be significantly different between the two groups. Furthermore, within the acromegaly group, RANKL levels were significantly higher in patients with active acromegaly compared to those with controlled acromegaly. Osteoprotegerin levels showed a positive correlation with the Framingham risk score (FRS) in the acromegaly group. Linear regression analysis revealed an association of OPG with FRS (adjusted R2 value of 21.7%). CONCLUSION OPG and RANKL may serve as potential markers for assessment of cardiovascular calcification and prediction of the cardiovascular risk status in acromegalic patients.
Collapse
Affiliation(s)
- Gokcen Unal Kocabas
- Division of Endocrinology and Metabolism Disorders, Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Turkey.
| | - Banu Sarer Yurekli
- Division of Endocrinology and Metabolism Disorders, Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Turkey
| | - Ilgin Yildirim Simsir
- Division of Endocrinology and Metabolism Disorders, Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Turkey
| | - Su Ozgur
- Ege University Translational Pulmonary Research Center, Regional Hub for Cancer Registration in North Africa, Central and Western Asia, WHO/IARC GICR, Izmir, Turkey
| | - Murat Aksit
- Department of Medical Biochemistry, Tepecik Training and Research Hospital, Izmir, Turkey
| | - Giray Bozkaya
- Department of Medical Biochemistry, Bozyaka Training and Research Hospital, Izmir, Turkey
| |
Collapse
|
2
|
Batman A, Yazıcı D, Dikbaş O, Ağbaht K, Saygılı ES, Demirci İ, Bursa N, Ayas G, Anıl C, Cesur M, Korkmaz FN, Bahçecioglu AB, Çorapçıoğlu D, Erdoğan MF, Bostan H, Calapkulu M, Hepşen S, Uçan B, Çakal E, Güler BY, Haymana C, İpekçi SH, Aydın S, Sezer H, Özışık S, Deyneli O, Alagöl F, Tanakol R, Eroğlu M, Mutlu Ü, Hacışahinoğulları H, Üzüm AK, Demir C, Koç G, Fırat SN, Omma T, İnce N, Polat ŞB, Topaloğlu O, Aydın C, Çakır B, Bahadır ÇT, Güven M, Sözen M, Selek A, Cantürk Z, Çetinarslan B, Aydemir M, Taşkaldıran I, Bozkuş Y, İyidir ÖT, Haydardedeoğlu FE, Basmaz SE, Ünal MÇ, Demir T, Oğuz A, Çelik Ö, Yilmaz M, Cimsir A, Kayıhan S, Uc ZA, Tekin S, Topaloğlu Ö, Saydam BÖ, Ünsal YA, Özer Ö, Yorulmaz G, Uğur K, Çakır SD, Aşık M, Unubol M, Genc S, Andac B, Okur M, Dogan O, Karakiliç E, Kocabas GU, Kirac CO, Cansu GB, Uygur MM, Pekkolay Z, Öztürk S, Güngüneş A, Gürkan E, Keskin L, Çağlayan K, Günay YE, İmre E, Şener SY, Kalkan AT, Gök DE, Şahin M. Subacute THYROiditis Related to SARS-CoV-2 VAccine and Covid-19 (THYROVAC Study): A Multicenter Nationwide Study. J Clin Endocrinol Metab 2023; 108:e1013-e1026. [PMID: 37186260 DOI: 10.1210/clinem/dgad235] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Revised: 04/13/2023] [Accepted: 04/17/2023] [Indexed: 05/17/2023]
Abstract
CONTEXT The aims of the study are to compare characteristics of subacute thyroiditis (SAT) related to different etiologies, and to identify predictors of recurrence of SAT and incident hypothyroidism. METHODS This nationwide, multicenter, retrospective cohort study included 53 endocrinology centers in Turkey. The study participants were divided into either COVID-19-related SAT (Cov-SAT), SARS-CoV-2 vaccine-related SAT (Vac-SAT), or control SAT (Cont-SAT) groups. RESULTS Of the 811 patients, 258 (31.8%) were included in the Vac-SAT group, 98 (12.1%) in the Cov-SAT group, and 455 (56.1%) in the Cont-SAT group. No difference was found between the groups with regard to laboratory and imaging findings. SAT etiology was not an independent predictor of recurrence or hypothyroidism. In the entire cohort, steroid therapy requirement and younger age were statistically significant predictors for SAT recurrence. C-reactive protein measured during SAT onset, female sex, absence of antithyroid peroxidase (TPO) positivity, and absence of steroid therapy were statistically significant predictors of incident (early) hypothyroidism, irrespective of SAT etiology. On the other hand, probable predictors of established hypothyroidism differed from that of incident hypothyroidism. CONCLUSION Since there is no difference in terms of follow-up parameters and outcomes, COVID-19- and SARS-CoV-2 vaccine-related SAT can be treated and followed up like classic SATs. Recurrence was determined by younger age and steroid therapy requirement. Steroid therapy independently predicts incident hypothyroidism that may sometimes be transient in overall SAT and is also associated with a lower risk of established hypothyroidism.
Collapse
Affiliation(s)
- Adnan Batman
- Department of Internal Medicine, Division of Endocrinology and Metabolism, School of Medicine, Koc University, 34010 Istanbul, Turkey
| | - Dilek Yazıcı
- Department of Internal Medicine, Division of Endocrinology and Metabolism, School of Medicine, Koc University, 34010 Istanbul, Turkey
| | - Oğuz Dikbaş
- Department of Endocrinology and Metabolism, Giresun University School of Medicine, 28200 Giresun, Turkey
| | - Kemal Ağbaht
- Department of Endocrinology and Metabolism, Defne Hospital, 31030 Hatay, Turkey
| | - Emre Sedar Saygılı
- Department of Internal Medicine, Division of Endocrinology and Metabolism, Faculty of Medicine, Canakkale Onsekiz Mart University, 17020 Canakkale, Turkey
| | - İbrahim Demirci
- Department of Endocrinology and Metabolism, Gulhane Training and Research Hospital, University of Health Sciences Turkey, 06010 Ankara, Turkey
| | - Nurbanu Bursa
- Department of Statistics Beytepe, Hacettepe University, 06230 Ankara, Turkey
| | - Görkem Ayas
- School of Medicine, Koc University, 34450 Istanbul, Turkey
| | - Cüneyd Anıl
- Department of Endocrinology and Metabolic Diseases, Güven Hospital, 06540 Ankara, Turkey
| | - Mustafa Cesur
- Department of Endocrinology and Metabolic Diseases, Güven Hospital, 06540 Ankara, Turkey
| | - Fatma Nur Korkmaz
- Department of Endocrinology and Metabolism, Ankara University, School of Medicine, 06050 Ankara, Turkey
| | - Adile Begüm Bahçecioglu
- Department of Endocrinology and Metabolism, Ankara University, School of Medicine, 06050 Ankara, Turkey
| | - Demet Çorapçıoğlu
- Department of Endocrinology and Metabolism, Ankara University, School of Medicine, 06050 Ankara, Turkey
| | - Murat Faik Erdoğan
- Department of Endocrinology and Metabolism, Ankara University, School of Medicine, 06050 Ankara, Turkey
| | - Hayri Bostan
- Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Diskapi Yildirim Beyazit Training and Research Hospital, 06110 Ankara, Turkey
| | - Murat Calapkulu
- Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Diskapi Yildirim Beyazit Training and Research Hospital, 06110 Ankara, Turkey
| | - Sema Hepşen
- Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Diskapi Yildirim Beyazit Training and Research Hospital, 06110 Ankara, Turkey
| | - Bekir Uçan
- Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Diskapi Yildirim Beyazit Training and Research Hospital, 06110 Ankara, Turkey
| | - Erman Çakal
- Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Diskapi Yildirim Beyazit Training and Research Hospital, 06110 Ankara, Turkey
| | - Bağdagül Yüksel Güler
- Department of Endocrinology and Metabolism, Gulhane Training and Research Hospital, University of Health Sciences Turkey, 06010 Ankara, Turkey
| | - Cem Haymana
- Department of Endocrinology and Metabolism, Gulhane Training and Research Hospital, University of Health Sciences Turkey, 06010 Ankara, Turkey
| | - Süleyman Hilmi İpekçi
- Department of Endocrinology, Hisar Intercontinental Hospital, 34768 Istanbul, Turkey
| | - Selami Aydın
- Department of Internal Medicine, Hisar Intercontinental Hospital, 34768 Istanbul, Turkey
| | - Havva Sezer
- Department of Internal Medicine, Division of Endocrinology and Metabolism, School of Medicine, Koc University, 34010 Istanbul, Turkey
| | - Seçil Özışık
- Department of Internal Medicine, Division of Endocrinology and Metabolism, School of Medicine, Koc University, 34010 Istanbul, Turkey
| | - Oğuzhan Deyneli
- Department of Internal Medicine, Division of Endocrinology and Metabolism, School of Medicine, Koc University, 34010 Istanbul, Turkey
| | - Faruk Alagöl
- Department of Endocrinology and Metabolism, VKV Amerikan Hospital-Koç University School of Medicine, 34365 Istanbul, Turkey
| | - Refik Tanakol
- Department of Endocrinology and Metabolism, VKV Amerikan Hospital-Koç University School of Medicine, 34365 Istanbul, Turkey
| | - Mustafa Eroğlu
- Department of Internal Medicine, Division of Endocrinology and Metabolism, Balikesir University Faculty of Medicine, 10145 Balikesir, Turkey
| | - Ümmü Mutlu
- Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Turkey
| | - Hülya Hacışahinoğulları
- Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Turkey
| | - Ayşe Kubat Üzüm
- Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Turkey
| | - Canan Demir
- Department of Internal Medicine, Division of Endocrinology and Metabolism, Atilim University School of Medicine, 06830 Ankara, Turkey
| | - Gönül Koç
- Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Ankara Training and Research Hospital, 06230 Ankara, Turkey
| | - Sevde Nur Fırat
- Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Ankara Training and Research Hospital, 06230 Ankara, Turkey
| | - Tülay Omma
- Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Ankara Training and Reasearch Hospital, 06230 Ankara, Turkey
| | - Nurcan İnce
- Department of Endocrinology and Metabolism, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara City Hospital, 06800 Ankara, Turkey
| | - Şefika Burçak Polat
- Department of Endocrinology and Metabolism, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara City Hospital, 06800 Ankara, Turkey
| | - Oya Topaloğlu
- Department of Endocrinology and Metabolism, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara City Hospital, 06800 Ankara, Turkey
| | - Cevdet Aydın
- Department of Endocrinology and Metabolism, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara City Hospital, 06800 Ankara, Turkey
| | - Bekir Çakır
- Department of Endocrinology and Metabolism, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara City Hospital, 06800 Ankara, Turkey
| | - Çiğdem Tura Bahadır
- Department of Endocrinology and Metabolism, Amasya University, School of Medicine, 05100 Amasya, Turkey
| | - Mehmet Güven
- Department of Endocrinology and Metabolism, Sirnak State Hospital, 73000 Sirnak, Turkey
| | - Mehmet Sözen
- Department of Endocrinology and Metabolism, Kocaeli University, School of Medicine, 41000 Kocaeli, Turkey
| | - Alev Selek
- Department of Endocrinology and Metabolism, Kocaeli University, School of Medicine, 41000 Kocaeli, Turkey
| | - Zeynep Cantürk
- Department of Endocrinology and Metabolism, Kocaeli University, School of Medicine, 41000 Kocaeli, Turkey
| | - Berrin Çetinarslan
- Department of Endocrinology and Metabolism, Kocaeli University, School of Medicine, 41000 Kocaeli, Turkey
| | - Mustafa Aydemir
- Department of Internal Medicine, Division of Endocrinology and Metabolism, Akdeniz University, School of Medicine, 07050 Antalya, Turkey
| | - Işılay Taşkaldıran
- Department of Endocrinology and Metabolism, Faculty of Medicine, Baskent University, 06790 Ankara, Turkey
| | - Yusuf Bozkuş
- Department of Endocrinology and Metabolism, Faculty of Medicine, Baskent University, 06790 Ankara, Turkey
| | - Özlem Turhan İyidir
- Department of Endocrinology and Metabolism, Faculty of Medicine, Baskent University, 06790 Ankara, Turkey
| | - Filiz Ekşi Haydardedeoğlu
- Department of Endocrinology and Metabolism, Faculty of Medicine, Baskent University, 79097 Adana, Turkey
| | - Seda Erem Basmaz
- Department of Endocrinology and Metabolism, Kocaeli Derince Training and Research Hospital, 41900 Kocaeli, Turkey
| | - Mehmet Çağrı Ünal
- Department of Endocrinology and Metabolism, Faculty of Medicine, Dokuz Eylul University, 35330 Izmir, Turkey
| | - Tevfik Demir
- Department of Endocrinology and Metabolism, Faculty of Medicine, Dokuz Eylul University, 35330 Izmir, Turkey
| | - Ayten Oğuz
- Department of Endocrinology and Metabolism, Faculty of Medicine, Biruni University, 34295 Istanbul, Turkey
| | - Özlem Çelik
- Department of Endocrinology and Metabolism, Faculty of Medicine, Acıbadem University, 34752 Istanbul, Turkey
| | - Merve Yilmaz
- Department of Endocrinology and Metabolism, Samsun State Hospital, 55060 Samsun, Turkey
| | - Aykut Cimsir
- Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Diskapi Yildirim Beyazit Training and Research Hospital, 06110 Ankara, Turkey
| | - Serdar Kayıhan
- Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Diskapi Yildirim Beyazit Training and Research Hospital, 06110 Ankara, Turkey
| | - Ziynet Alphan Uc
- Department of Endocrinology and Metabolism, Usak University, Usak Training and Research Hospital, 64300 Usak, Turkey
| | - Sakin Tekin
- Department of Endocrinology and Metabolism, Faculty of Medicine, Zonguldak Bulent Ecevit University, 67100 Zonguldak, Turkey
| | - Ömercan Topaloğlu
- Department of Endocrinology and Metabolism, Faculty of Medicine, Zonguldak Bulent Ecevit University Obesity and Diabetes Practice and Research Center, 67100 Zonguldak, Turkey
| | - Başak Özgen Saydam
- Department of Endocrinology and Metabolism, Ankara Yildirim Beyazit University, Yenimahalle Training and Research Hospital, 06370 Ankara, Turkey
| | - Yasemin Aydoğan Ünsal
- Department of Endocrinology and Metabolism, Ankara Yildirim Beyazit University, Yenimahalle Training and Research Hospital, 06370 Ankara, Turkey
| | - Özge Özer
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Eskisehir Osmangazi University, 26040 Eskisehir, Turkey
| | - Göknur Yorulmaz
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Eskisehir Osmangazi University, 26040 Eskisehir, Turkey
| | - Kader Uğur
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Fırat University, 23119 Elazıg, Turkey
| | - Sezin Doğan Çakır
- Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Istanbul Taksim Training and Research Hospital, 34433 Istanbul, Turkey
| | - Mehmet Aşık
- Endocrinologist, Private Office, Bodrum, 48400 Mugla, Turkey
| | - Mustafa Unubol
- Department of Endocrinology and Metabolism, School of Medicine, Adnan Menderes University, 09100 Aydin, Turkey
| | - Selin Genc
- Department of Endocrinology and Metabolism, School of Medicine, Inonu University, 44280 Malatya, Turkey
| | - Burak Andac
- Department of Endocrinology and Metabolism, School of Medicine, Trakya University, 22130 Edirne, Turkey
| | - Mine Okur
- Department of Endocrinology and Metabolism, School of Medicine, Trakya University, 22130 Edirne, Turkey
| | - Ozlem Dogan
- Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Haseki Training and Research Hospital, 34096 Istanbul, Turkey
| | - Ersen Karakiliç
- Department of Internal Medicine, Division of Endocrinology and Metabolism, Faculty of Medicine, Canakkale Onsekiz Mart University, 17020 Canakkale, Turkey
| | - Gokcen Unal Kocabas
- Department of Endocrinology and Metabolism, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
| | - Cem Onur Kirac
- Department of Endocrinology and Metabolism, Kahramanmaras Necip Fazil City Hospital, 46050 Kahramanmaras, Turkey
| | - Güven Barış Cansu
- Department of Endocrinology and Metabolism, School of Medicine, Kutahya University of Health Sciences, 43100 Kutahya, Turkey
| | - Meliha Melin Uygur
- Department of Endocrinology and Metabolism, School of Medicine, Marmara University, Pendik Training and Research Hospital, 34899 Istanbul, Turkey
| | - Zafer Pekkolay
- Department of Endocrinology and Metabolism, School of Medicine, Dicle University, 21100 Diyarbakir, Turkey
| | - Sadettin Öztürk
- Department of Endocrinology and Metabolism, School of Medicine, Gaziantep University, 27850 Gaziantep, Turkey
| | - Aşkın Güngüneş
- Department of Endocrinology and Metabolism, School of Medicine, Kırıkkale University, 71300 Kırıkkale, Turkey
| | - Eren Gürkan
- Department of Endocrinology and Metabolism, School of Medicine, Hatay Mustafa Kemal University, 31001 Hatay, Turkey
| | - Lezzan Keskin
- Department of Endocrinology and Metabolism, School of Medicine, Malatya Turgut Ozal University, Malatya Training and Research Hospital, 44000 Malatya, Turkey
| | - Kenan Çağlayan
- Department of Endocrinology and Metabolism, School of Medicine, Baskent University Istanbul Hospital, 34662 Istanbul, Turkey
| | - Yasemin Emur Günay
- Department of Endocrinology and Metabolism, School of Medicine, Karadeniz Technical University, 61080 Trabzon, Turkey
| | - Eren İmre
- Department of Endocrinology and Metabolism, Dr Ersin Arslan Education and Research Hospital, 27010 Gaziantep, Turkey
| | - Selcuk Yusuf Şener
- Department of Endocrinology and Metabolism, Pendik Medikalpark Hospital, 34899 Istanbul, Turkey
| | - Ahmet Toygar Kalkan
- Department of Endocrinology and Metabolism, Kastamonu Research and Training Hospital, 37150 Kastamonu, Turkey
| | - Deniz Engin Gök
- Department of Endocrinology and Metabolism, Lokman Hekim Hospital, 06700 Ankara, Turkey
| | - Mustafa Şahin
- Department of Endocrinology and Metabolism, Ankara University, School of Medicine, 06050 Ankara, Turkey
| |
Collapse
|
3
|
Alarslan P, Unal Kocabas G, Demir I, Guler A, Bozkaya G, Aslanipour B, Calan M. Increased urocortin 3 levels are associated with the risk of having type 2 diabetes mellitus. J Diabetes 2020; 12:474-482. [PMID: 31893569 DOI: 10.1111/1753-0407.13020] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Revised: 12/07/2019] [Accepted: 12/29/2019] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Urocortin 3 (UCN3) is a peptide hormone playing a pivotal role in glucose and lipid metabolisms. However, its clinical implications remain unclear. Our aims were to investigate the altered levels of UCN3 in newly diagnosed type 2 diabetes mellitus (nT2DM) patients in comparison to subjects with normal glucose tolerance (NGT) and to determine the presence of any possible link between UCN3 levels and metabolic parameters. METHODS Eighty nT2DM and 80 age-, body mass index (BMI)-, and gender-matched NGT subjects were enrolled into this case-control study. The circulating UCN3 levels were measured using the enzyme-linked immunoabsorbent assay (ELISA). Metabolic parameters of enrolled subjects were also determined. A standard 75-g 2-hour oral glucose tolerance test was used for diagnosis of type 2 diabetes mellitus (T2DM). RESULTS UCN3 levels were higher in subjects with nT2DM than in controls (115.64 ± 39.26 vs 86.16 ± 22.81 pg/mL, P < .001). UCN3 levels were increased in subjects with metabolic syndrome compared to subjects without metabolic syndrome in both nT2DM and NGT groups. UCN3 levels showed a positive correlation with BMI in both groups. Moreover, UCN3 levels were positively and independently associated with insulin, fasting blood glucose, insulin resistance, 2-hour plasma glucose, glycosylated hemoglobin, and triglycerides, whereas UCN3 levels were negatively and independently associated with high-density lipoprotein cholesterol. According to logistic regression analysis, increased risk of T2DM and metabolic syndrome were parallel with the highest elevated levels of UCN3. CONCLUSIONS Increased levels of UCN3 are associated with unfavorable metabolic profiles in T2DM, indicating a potential role of UCN3 in glucose and lipid metabolisms in T2DM.
Collapse
Affiliation(s)
- Pınar Alarslan
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey
| | - Gokcen Unal Kocabas
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey
| | - Ismail Demir
- Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey
| | - Aslı Guler
- Department of Family Physician, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey
| | - Giray Bozkaya
- Department of Clinical Biochemistry, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey
| | - Behnaz Aslanipour
- Department of Biotechnology, Graduate School of Natural and Applied Sciences, Ege University, Izmir, Turkey
| | - Mehmet Calan
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey
| |
Collapse
|
4
|
Bicer M, Alan M, Alarslan P, Guler A, Kocabas GU, Imamoglu C, Aksit M, Bozkaya G, Isil AM, Baloglu A, Aslanipoiur B, Calan M. Circulating insulin-like peptide 5 levels and its association with metabolic and hormonal parameters in women with polycystic ovary syndrome. J Endocrinol Invest 2019; 42:303-312. [PMID: 29956214 DOI: 10.1007/s40618-018-0917-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2018] [Accepted: 06/19/2018] [Indexed: 02/01/2023]
Abstract
PURPOSE Insulin-like peptide 5 (INSL5) is a gut peptide hormone that is a member of relaxin/insulin superfamily. Growing evidence implicates the crucial role of the peptide in some metabolisms including food intake, glucose homeostasis and reproductive system. Polycystic ovary syndrome (PCOS) is involved in both reproductive and metabolic issues. The aim of the study was determination of circulating levels of INSL5 alteration in women with PCOS and evaluation of the relationship between INSL5 and hormonal-metabolic parameters as well as carotid intima media thickness (cIMT). METHODS A total of 164 subjects were recruited in this cross-sectional study (82 women with PCOS and 82 age- and BMI-matched controls). Circulating INSL5 levels were assessed via ELISA method. High-resolution B-mode ultrasound was used to measure cIMT. The hormonal and metabolic parameters of the recruited subjects were determined. RESULTS Circulating INSL5 levels were significantly elevated in women with PCOS compared to controls (27.63 ± 7.74 vs. 19.90 ± 5.85 ng/ml, P < 0.001). The mean values of INSL5 were significantly higher in overweight subjects compared to lean weight subjects in both groups. The women with PCOS having insulin resistance have increased INSL5 compared to those of PCOS subjects without insulin resistance. INSL5 is associated with insulin resistance, BMI, luteinizing hormone and free androgen index. Multivariate logistic regression analyses revealed that the odds ratio for having PCOS in the highest tertile of INSL5 was higher than in the lowest tertile. CONCLUSIONS PCOS subjects exhibited an elevation in circulating INSL5 levels along with a link between INSL5 level induction and metabolic-hormonal parameters.
Collapse
Affiliation(s)
- M Bicer
- Department of Obstetrics and Gynecology, Medical Park Hospital, 35575, Izmir, Turkey
| | - M Alan
- Department of Obstetrics and Gynecology, Izmir Tepecik Training and Research Hospital, Tepecik, 35120, Izmir, Turkey
| | - P Alarslan
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, 35170, Izmir, Turkey
| | - A Guler
- Department of Family Physician, Izmir Bozyaka Training and Research Hospital, Bozyaka, 35170, Izmir, Turkey
| | - G U Kocabas
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, 35170, Izmir, Turkey
| | - C Imamoglu
- Department of Radiology, Izmir Bozyaka Training and Research Hospital, Bozyaka, 35170, Izmir, Turkey
| | - M Aksit
- Department of Biochemistry and Clinical Biochemistry, Izmir Tepecik Training and Research Hospital, Tepecik, 35120, Izmir, Turkey
| | - G Bozkaya
- Department of Biochemistry and Clinical Biochemistry, Izmir Bozyaka Training and Research Hospital, Bozyaka, 35170, Izmir, Turkey
| | - A M Isil
- Department of Family Physician, Izmir Bozyaka Training and Research Hospital, Bozyaka, 35170, Izmir, Turkey
| | - A Baloglu
- Department of Obstetrics and Gynecology, Private Gynecology Clinic, 35172, Izmir, Turkey
| | - B Aslanipoiur
- Department of Bioengineering, Faculty of Engineering, Ege University, Izmir, Turkey
| | - Mehmet Calan
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, 35170, Izmir, Turkey.
| |
Collapse
|
5
|
Demirpence M, Guler A, Yilmaz H, Sayin A, Pekcevik Y, Turkon H, Colak A, Ari EM, Aslanipour B, Kocabas GU, Calan M. Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly? J Endocrinol Invest 2019; 42:207-215. [PMID: 29804270 DOI: 10.1007/s40618-018-0905-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/31/2017] [Accepted: 05/18/2018] [Indexed: 02/07/2023]
Abstract
PURPOSE Acromegaly is a rare disorder existed in the result of overproduction of growth hormone (GH). The disorder is associated with increased cardiovascular risk factors and metabolic abnormalities. Urotensin II (UII), a secreted vasoactive peptide hormone, belonging somatostatin superfamily, plays an essential role in atherosclerosis and glucose metabolism. The aim of this study was to ascertain whether circulating UII levels are altered in subjects with acromegaly, and to describe the relationship between UII and hormonal or cardiometabolic parameters. METHODS This cross-sectional study included 41 subjects with active acromegaly, 28 subjects with controlled acromegaly, and 37 age- and BMI-matched controls without acromegaly. Hormonal and metabolic features of the subjects as well as carotid intima media thickness (cIMT) and epicardial fat thickness (EFT) were defined. Circulation of UII levels was determined via ELISA. RESULTS Both active and controlled acromegalic subjects showed a significant elevation of circulating levels of UII with respect to controls. There was no remarkable difference in circulating levels of UII between active and controlled acromegalic groups. Both cIMT and EFT were remarkably increased in acromegaly subjects comparing to controls. UII positively correlated with cIMT, EFT, BMI, and HOMA-IR. There was no correlation between UII and GH, insulin-like growth factor-1. According to the results obtained from regression models, UII levels independently predicted cIMT and EFT. CONCLUSION Elevated UII levels are associated with severity of cardiovascular risk factors including cIMT and EFT in acromegalic subjects.
Collapse
Affiliation(s)
- M Demirpence
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Tepecik Training and Research Hospital, Tepecik, 35120, Izmir, Turkey
| | - A Guler
- Department of Family Physician, Izmir Bozyaka Training and Research Hospital, Bozyaka, 35170, Izmir, Turkey
| | - H Yilmaz
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Tepecik Training and Research Hospital, Tepecik, 35120, Izmir, Turkey
| | - A Sayin
- Department of Cardiology, Izmir Tepecik Research and Training Hospital, Tepecik, 35120, Izmir, Turkey
| | - Y Pekcevik
- Department of Radiology, Izmir Tepecik Training and Research Hospital, Tepecik, 35120, Izmir, Turkey
| | - H Turkon
- Department of Medical Biochemistry, Faculty of Medicine, Canakkale Onsekiz Mart University, 17120, Canakkale, Turkey
| | - A Colak
- Department of Clinical Biochemistry, Izmir Tepecik Training and Research Hospital, Tepecik, 35120, Izmir, Turkey
| | - E M Ari
- Department of Clinical Biochemistry, Izmir Tepecik Training and Research Hospital, Tepecik, 35120, Izmir, Turkey
| | - B Aslanipour
- Department of Bioengineering, Faculty of Engineering, Ege University, Bornova, 35100, Izmir, Turkey
| | - G U Kocabas
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, 35170, Izmir, Turkey
| | - M Calan
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, 35170, Izmir, Turkey.
| |
Collapse
|
6
|
Yurekli BS, Kutbay NO, Aksit M, Suner A, Simsir IY, Seckiner S, Kocabas GU, Bozkaya G, Saygili F. Acromegaly is associated with high fibroblast growth factor-21 levels. J Endocrinol Invest 2019; 42:53-60. [PMID: 29754168 DOI: 10.1007/s40618-018-0885-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Accepted: 04/03/2018] [Indexed: 11/11/2022]
Abstract
PURPOSE Fibroblast growth factor-21 (FGF-21) is a member of fibroblast growth factor family. Both growth hormone (GH) and FGF-21 take place in the regulation of glucose and lipid metabolism. We aimed to investigate FGF-21 levels in acromegaly which is characterized by excess GH levels and is associated with comorbidities and altered body composition. METHODS We studied 43 subjects (21 females and 22 males, mean age of 50.0 ± 12.8) with acromegaly. The control group consisted of 40 gender- and age-matched subjects (25 females and 15 males, mean age of 48.8 ± 8.8). Acromegaly patients were classified into two groups; active acromegaly (AA; n = 26) and controlled acromegaly (CA; n = 17). Metabolic, anthropometric and laboratory values of subjects were recorded. FGF-21 level was measured by ELISA assay. RESULTS Median FGF-21 levels were significantly higher in acromegaly group compared to control group (85.5 vs. 59.0 pg/mL, p = 0.02, respectively). In the multiple regression model, FPG, A1c, HOMA-IR, glucose intolerance, BMI, visceral fat, hs-CRP, presence of hypertension, dyslipidemia and acromegaly were included as independent variables to explain variability of plasma FGF-21 levels in whole study group. The presence of acromegaly was the only determinant of increased FGF-21 levels in the whole study group (β coefficient = 0.253, p = 0.006). CONCLUSION FGF-21 levels were increased significantly in acromegaly group. Increased FGF-21 levels were significantly and independently associated with the state of acromegaly. Acromegaly may also be a FGF-21 resistance state independent from insulin resistance, glucose intolerance, obesity, hypertension and dyslipidemia.
Collapse
Affiliation(s)
- B S Yurekli
- Division of Endocrinology, Ege University Faculty of Medicine, Ankara Street, Bornova, Izmir, Turkey.
| | - N O Kutbay
- Division of Endocrinology, Ege University Faculty of Medicine, Ankara Street, Bornova, Izmir, Turkey
| | - M Aksit
- Department of Biochemistry, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
| | - A Suner
- Department of Biostatistics, Ege University Faculty of Medicine, Izmir, Turkey
| | - I Y Simsir
- Division of Endocrinology, Ege University Faculty of Medicine, Ankara Street, Bornova, Izmir, Turkey
| | - S Seckiner
- Department of Nutrition and Dietetics, Ege University Faculty of Medicine, Izmir, Turkey
| | - G U Kocabas
- Division of Endocrinology, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
| | - G Bozkaya
- Department of Biochemistry, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
| | - F Saygili
- Division of Endocrinology, Ege University Faculty of Medicine, Ankara Street, Bornova, Izmir, Turkey
| |
Collapse
|
7
|
Yurekli BS, Kocabas GU, Aksit M, Kutbay NO, Suner A, Yurekli I, Cakir H, Bozkaya G, Cetinkalp S. The low levels of bone morphogenic protein-4 and its antagonist noggin in type 2 diabetes. Hormones (Athens) 2018; 17:247-253. [PMID: 29943307 DOI: 10.1007/s42000-018-0041-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Accepted: 02/23/2018] [Indexed: 11/11/2022]
Abstract
OBJECTIVE Bone morphogenic protein-4 (BMP-4) is a proinflammatory cytokine which is controlled by BMP-4 antagonists. Our aim was to investigate the levels of BMP-4 and its antagonists, noggin and matrix Gla protein (MGP), in prediabetes and diabetes. DESIGN One hundred and forty-two type 2 diabetic, 32 prediabetic, and 58 control subjects participated in this cross-sectional study. BMP-4, noggin, and MGP were measured with the ELISA method. RESULTS There was a significant difference between the three groups in relation to sex, hypertension, fasting plasma glucose, HbA1c, lipid profiles, and diastolic blood pressure (p < 0.05). BMP-4 levels were significantly lower in the diabetic group compared to the control group (108.5 and 127.5 ng/mL, respectively, p < 0.001 diabetes vs. control). Noggin levels were significantly lower in the diabetic group compared to the prediabetic and control groups (10.5, 11.5, and 12.0 ng/mL, as median, respectively, p < 0.001; diabetes vs. control, p = 0.002; diabetes vs. prediabetes). BMP-4 was associated significantly with noggin in the entire study population (ß coefficient = 0.796, p < 0.001). Receiver operating characteristic (ROC) curve analysis showed that the area under the ROC curve was 0.708 (95% CI 0.551-0.864, p = 0.011) for BMP-4 levels. The optimal cutoff value of BMP-4 for detecting albuminuria was 118.5 ng/mL for which sensitivity was 71.4% and specificity was 66.4%. CONCLUSIONS BMP-4 and noggin levels were lower in the diabetic group. High BMP-4 levels were significantly associated with albuminuria. Further studies are warranted to determine the role of BMP-4 in the pathogenic processes underlying albuminuria and hyperglycemia in patients with type 2 diabetes.
Collapse
Affiliation(s)
- Banu Sarer Yurekli
- Department of Endocrinology, Ege University Faculty of Medicine, Ankara Street, Bornova, 35100, Izmir, Turkey.
| | - Gokcen Unal Kocabas
- Department of Endocrinology, Bozyaka Education and Research Hospital, Izmir, Turkey
| | - Murat Aksit
- Department of Biochemistry, Bozyaka Education and Research Hospital, Izmir, Turkey
| | - Nilufer Ozdemir Kutbay
- Department of Endocrinology, Ege University Faculty of Medicine, Ankara Street, Bornova, 35100, Izmir, Turkey
| | - Aslı Suner
- Department of Biostatistics and Medical Informatics, Ege University Faculty of Medicine, Izmir, Turkey
| | - Ismail Yurekli
- Department of Cardiovascular Surgery, Izmir Ataturk Education and Research Hospital, Izmir, Turkey
| | - Habib Cakir
- Department of Cardiovascular Surgery, Izmir Ataturk Education and Research Hospital, Izmir, Turkey
| | - Giray Bozkaya
- Department of Biochemistry, Bozyaka Education and Research Hospital, Izmir, Turkey
| | - Sevki Cetinkalp
- Department of Endocrinology, Ege University Faculty of Medicine, Ankara Street, Bornova, 35100, Izmir, Turkey
| |
Collapse
|
8
|
Bicer M, Guler A, Unal Kocabas G, Imamoglu C, Baloglu A, Bilgir O, Yuksel A, Bozkaya G, Calan M. Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome. Endocr Res 2017; 42:145-153. [PMID: 27911121 DOI: 10.1080/07435800.2016.1255896] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
PURPOSE Endocan is a proteoglycan secreted mainly from endothelial cells. It has been implicated that there is a link between endocan and endothelial dysfunction. Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disease associated with increased risk of cardiovascular events. The aims of this study were to ascertain whether circulating endocan levels are altered in women with PCOS, and whether there is an association between endocan and carotid intima media thickness (cIMT). MATERIALS AND METHODS This cross-sectional study included 80 women with PCOS and 80 age- and BMI-matched controls without PCOS. Circulating endocan levels were measured using ELISA. Metabolic, hormonal parameters and cIMT were determined. 2-h oral glucose tolerance test (2-h OGTT) was performed on all women. RESULTS Circulating endocan levels were significantly elevated in women with PCOS compared with controls (5.99 ± 2.37 vs. 3.66 ± 1.79 ng/ml, P < 0.001). Endocan levels positively correlated with BMI, homeostasis model assessment of insulin resistance (HOMA-IR), free androgen index (FAI), high-sensitivity C-reactive protein (hs-CRP), and cIMT in both PCOS and control groups. Endocan levels did not correlate with fasting blood glucose, 2-h OGTT, A1C and lipid parameters. Multiple linear regression analysis revealed that endocan is an independent predictor for cIMT (β = 0.128, 95% CI = 0.118-0.138, P = 0.011). CONCLUSIONS Circulating endocan levels are significantly higher in women with PCOS and endocan is independently associated with cIMT. Elevated endocan levels can be a predictor of increased cardiovascular risk in PCOS subjects.
Collapse
Affiliation(s)
- Merve Bicer
- a Department of Obstetrics and Gynecology , Izmir University School of Medicine, Medical Park Hospital , Izmir , Turkey
| | - Aslı Guler
- b Department of Family Physician , Izmir Bozyaka Training and Research Hospital , Izmir , Turkey
| | - Gokcen Unal Kocabas
- c Department of Internal Medicine , Division of Endocrinology and Metabolism, Izmir Bozyaka Training and Research Hospital , Izmir , Turkey
| | - Cetin Imamoglu
- d Department of Radiology , Izmir Bozyaka Training and Research Hospital , Izmir , Turkey
| | - Ali Baloglu
- e Department of Obstetrics and Gynecology , Private Gynecology Clinic , Izmir , Turkey
| | - Oktay Bilgir
- f Department of Internal Medicine , Izmir Bozyaka Training and Research Hospital , Izmir , Turkey
| | - Arif Yuksel
- f Department of Internal Medicine , Izmir Bozyaka Training and Research Hospital , Izmir , Turkey
| | - Giray Bozkaya
- g Department of Biochemistry and Clinical Biochemistry , Izmir Bozyaka Training and Research Hospital , Izmir , Turkey
| | - Mehmet Calan
- c Department of Internal Medicine , Division of Endocrinology and Metabolism, Izmir Bozyaka Training and Research Hospital , Izmir , Turkey
| |
Collapse
|
9
|
Calan M, Guler A, Unal Kocabas G, Alarslan P, Bicer M, Imamoglu C, Yuksel A, Bozkaya G, Bilgir O. Association of kallistatin with carotid intima-media thickness in women with polycystic ovary syndrome. MINERVA ENDOCRINOL 2017; 43:236-245. [PMID: 28294594 DOI: 10.23736/s0391-1977.17.02586-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Kallistatin is a secreted protein that acts as a tissue kallikrein inhibitor. It has anti-inflammatory, antioxidant and vasoprotective properties. Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disease associated with low-grade chronic inflammation and multiple risk factors for cardiovascular diseases. The aims of this study were to ascertain whether circulating kallistatin levels are altered in women with PCOS, and whether there is an association between kallistatin and carotid intima-media thickness (cIMT) as well as inflammatory markers high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-α (TNF-α). METHODS This cross-sectional study included 75 women with PCOS and 75 age- and BMI-matched controls without PCOS. Circulating kallistatin and TNF-α levels were measured using ELISA. Metabolic and hormonal parameters, hs-CRP levels and cIMT were also determined. All subjects underwent the 2-hour oral glucose tolerance test (2-h OGTT). RESULTS Circulating kallistatin levels were significantly elevated in women with PCOS compared to controls (6.31±2.09 vs. 4.79±2.26 ng/mL, P<0.001). Inflammatory markers hs-CRP and TNF-α were found to be elevated in women with PCOS. Kallistatin levels positively correlated with insulin, insulin resistance index (HOMA-IR), free androgen index, hs-CRP, TNF-α and cIMT in both PCOS and control groups. Kallistatin levels did not show correlation with BMI, blood pressure, fasting blood glucose, 2-h OGTT or HbA1c. Multiple linear regression analysis revealed that kallistatin is an independent predictor for cIMT (β=0.131, 95% CI: 0.114-0.150, P=0.019). CONCLUSIONS Kallistatin levels may provide useful information regarding cardiovascular risk in women with PCOS.
Collapse
Affiliation(s)
- Mehmet Calan
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey -
| | - Aslı Guler
- Department of Family Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey
| | - Gokcen Unal Kocabas
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey
| | - Pınar Alarslan
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey
| | - Merve Bicer
- Department of Obstetrics and Gynecology, Medical Park Hospital, Izmir, Turkey
| | - Cetin Imamoglu
- Department of Radiology, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey
| | - Arif Yuksel
- Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey
| | - Giray Bozkaya
- Department of Biochemistry and Clinical Biochemistry, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey
| | - Oktay Bilgir
- Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey
| |
Collapse
|
10
|
Gursoy Calan O, Calan M, Yesil Senses P, Unal Kocabas G, Ozden E, Sari KR, Kocar M, Imamoglu C, Senses YM, Bozkaya G, Bilgir O. Increased adipsin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2016; 85:910-917. [PMID: 27434652 DOI: 10.1111/cen.13157] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/05/2016] [Revised: 06/25/2016] [Accepted: 07/14/2016] [Indexed: 01/14/2023]
Abstract
CONTEXT Adipsin, a protein secreted mainly from the adipose tissue, is a structural homologous of complement factor D, a rate-limiting enzyme of the alternative complement system. Growing evidence suggests that the alternative complement system plays a role both in the regulation of energy homoeostasis and in the atherosclerosis. Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disease. OBJECTIVE To ascertain whether circulating adipsin levels are altered in women with PCOS, and whether there is an association between adipsin and metabolic parameters or carotid intima media thickness (CIMT). PARTICIPANTS A total of 144 women with PCOS and 144 age- and BMI-matched controls without PCOS were recruited for this cross-sectional study. MAIN OUTCOME MEASURES Circulating adipsin levels were measured using ELISA. Metabolic, hormonal parameters and CIMT were also determined. RESULTS Adipsin levels were significantly elevated in women with PCOS compared with controls (91·52 ± 14·11 vs 60·31 ± 9·71 ng/ml, P < 0·001). Adipsin positively correlated with BMI, homoeostasis model assessment of insulin resistance (HOMA-IR), free testosterone, high-sensitivity C-reactive protein (hs-CRP) and CIMT in both groups. Multivariate logistic regression analyses revealed that the odds ratio for PCOS was 3·25 for patients in the highest quartile of adipsin compared with those in the lowest quartile (OR=3·25, 95% CI=2·64-4·00, P = 0·016). Our findings further indicate that BMI, HOMA-IR, hs-CRP and free testosterone are independent factors influencing serum adipsin levels and that adipsin is an independent predictor for CIMT. CONCLUSION Circulating adipsin levels are significantly higher in women with PCOS, and the peptide is closely related to increased cardiovascular risk and metabolic disturbances.
Collapse
Affiliation(s)
- Ozlem Gursoy Calan
- Department of Biochemistry and Clinical Biochemistry (PCOS Research Group), Dokuz Eylul University Faculty of Medicine, Izmir, Turkey
| | - Mehmet Calan
- Division of Endocrinology and Metabolism (PCOS Research Group), Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey
| | | | - Gokcen Unal Kocabas
- Division of Endocrinology and Metabolism (PCOS Research Group), Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey
| | - Ebru Ozden
- Department of Internal Medicine (PCOS Research Group), Izmir Bozyaka Training and Research Hospital, Izmir, Turkey
| | - Kerime R Sari
- Department of Internal Medicine (PCOS Research Group), Izmir Bozyaka Training and Research Hospital, Izmir, Turkey
| | - Merve Kocar
- Department of Internal Medicine (PCOS Research Group), Izmir Bozyaka Training and Research Hospital, Izmir, Turkey
| | - Cetin Imamoglu
- Department of Radiology, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey
| | - Yasar M Senses
- Department of Bioengineering, Ege University, Izmir, Turkey
| | - Giray Bozkaya
- Department of Biochemistry and Clinical Biochemistry, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey
| | - Oktay Bilgir
- Department of Internal Medicine (PCOS Research Group), Izmir Bozyaka Training and Research Hospital, Izmir, Turkey
| |
Collapse
|
11
|
Calan M, Kume T, Yilmaz O, Arkan T, Kocabas GU, Dokuzlar O, Aygün K, Oktan MA, Danıs N, Temur M. A possible link between luteinizing hormone and macrophage migration inhibitory factor levels in polycystic ovary syndrome. Endocr Res 2016; 41:261-9. [PMID: 26913980 DOI: 10.3109/07435800.2015.1135442] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
PURPOSE Macrophage migration inhibitory factor (MIF) is a multifunctional cytokine that plays a role in metabolic and inflammatory processes. Increasing evidence suggests that there is a link between MIF and ovulation. We aimed to evaluate plasma MIF levels in women with polycystic ovary syndrome (PCOS) and to determine whether MIF levels differ between the follicular phase and mid-cycle of the menstrual cycle in eumenorrheic women. METHODS Ninety women with PCOS and 80 age- and BMI-matched healthy eumenorrheic women were consecutively recruited into this prospective observational study. For all subjects, plasma MIF levels in the early follicular phase were measured by ELISA; for the 40 healthy controls, MIF levels were also measured during mid-cycle of the same menstrual cycle. RESULTS Plasma MIF levels were significantly higher in women with PCOS than in eumenorrheic women (14.16 ± 1.59 vs. 10.39 ± 0.70 ng/ml; p < 0.001). MIF levels were significantly higher at mid-cycle than in the follicular phase in eumenorrheic women (11.15 ± 0.61 vs. 10.56 ± 0.82 ng/ml; p < 0.001). MIF was positively correlated with BMI, high sensitivity C-reactive protein (hs-CRP), and homeostasis model assessment of insulin resistance (HOMA-IR) in both groups. MIF was positively correlated with luteinizing hormone (LH) and free-testosterone only in the PCOS group. Binary logistic regression analyses revealed that the odds ratio (OR) for PCOS independently increases linearly with elevated MIF (OR = 1.385, 95% CI = 1.087-1.764, p = 0.017). CONCLUSION MIF may play a crucial role in the reproductive system in women, including the development of PCOS and normal ovulation.
Collapse
Affiliation(s)
- Mehmet Calan
- a Division of Endocrinology and Metabolism, Department of Internal Medicine , Dokuz Eylul University Medical School , Izmir , Turkey
| | - Tuncay Kume
- b Department of Medical Biochemistry , Dokuz Eylul University Medical School , Izmir , Turkey
| | - Ozgur Yilmaz
- c Department of Obstetrics and Gynecology , Manisa Merkezefendi Hospital , Manisa , Turkey
| | - Tugba Arkan
- a Division of Endocrinology and Metabolism, Department of Internal Medicine , Dokuz Eylul University Medical School , Izmir , Turkey
| | - Gokcen Unal Kocabas
- d Division of Endocrinology and Metabolism, Department of Internal Medicine , Izmir Bozyaka Training and Research Hospital , Izmir , Turkey
| | - Ozge Dokuzlar
- e Department of Internal Medicine , Dokuz Eylul University Medical School , Izmir , Turkey
| | - Kemal Aygün
- e Department of Internal Medicine , Dokuz Eylul University Medical School , Izmir , Turkey
| | - Mehmet Asi Oktan
- e Department of Internal Medicine , Dokuz Eylul University Medical School , Izmir , Turkey
| | - Nilay Danıs
- e Department of Internal Medicine , Dokuz Eylul University Medical School , Izmir , Turkey
| | - Muzaffer Temur
- c Department of Obstetrics and Gynecology , Manisa Merkezefendi Hospital , Manisa , Turkey
| |
Collapse
|
12
|
Kume T, Calan M, Yilmaz O, Kocabas GU, Yesil P, Temur M, Bicer M, Calan OG. A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. J Endocrinol Invest 2016; 39:747-54. [PMID: 26969461 DOI: 10.1007/s40618-016-0453-5] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Accepted: 02/22/2016] [Indexed: 12/29/2022]
Abstract
CONTEXT Adropin is a peptide hormone implicated in the regulation of insulin sensitivity and energy homeostasis. Polycystic ovary syndrome (PCOS) is a metabolic and reproductive disease associated with insulin resistance. It has been demonstrated that various inflammatory markers increased in PCOS including TNF-α. TNF-α regulates the secretion of certain peptides which play a crucial role in glucose and lipid homeostasis. There is also some evidence of a link between TNF-α and adropin. OBJECTIVE To ascertain whether there is an association between circulating adropin levels and TNF-α in PCOS. PATIENTS AND DESIGN 152 women with PCOS and 152 age- and body mass index-matched controls without PCOS were recruited for this cross-sectional study. MAIN OUTCOME MEASURES Adropin and TNF-α levels were measured using ELISA. RESULTS Adropin levels were lower in the PCOS group compared with the control group (7.43 ± 0.79 vs. 9.42 ± 0.76 ng/ml, P < 0.001), whereas TNF-α levels were higher (49.93 ± 3.39 vs. 35.83 ± 2.47 pg/ml, P < 0.001). A strongly negative correlation was found between circulating adropin levels and TNF-α levels in women with PCOS (r = -0.407, P < 0.001). Binary logistic regression analysis revealed that decreased adropin levels were significantly associated with high odds of having PCOS, although, after adjustment for TNF-α, this link vanished. Additionally, multiple linear regression analysis showed that HOMA-IR and TFN-α independently predicted adropin levels. CONCLUSIONS Serum adropin levels are significantly decreased in PCOS and are inversely associated with TNF-α. Further dissection of the nature of this association can open new therapeutic options for metabolic diseases.
Collapse
Affiliation(s)
- T Kume
- Department of Biochemistry and Clinical Biochemistry, Dokuz Eylul University Faculty of Medicine, 35340, Inciralti, Izmir, Turkey
| | - M Calan
- Division of Endocrinology and Metabolism (PCOS Research Group), Department of Internal Medicine, Dokuz Eylul University Faculty of Medicine, 35340, Inciralti, Izmir, Turkey.
| | - O Yilmaz
- Department of Obstetrics and Gynecology, Manisa Merkezefendi State Hospital, 45020, Merkezefendi, Manisa, Turkey
| | - G U Kocabas
- Division of Endocrinology and Metabolism, Department of Internal Medicine (PCOS Research Group), Izmir Bozyaka Training and Research Hospital, 35170, Bozyaka, Izmir, Turkey
| | - P Yesil
- Department of Bioengineering, Ege University, 35100, Bornova, Izmir, Turkey
| | - M Temur
- Department of Obstetrics and Gynecology, Manisa Merkezefendi State Hospital, 45020, Merkezefendi, Manisa, Turkey
| | - M Bicer
- Department of Obstetrics and Gynecology, Medical Park Hospital, Izmir University Faculty of Medicine, 35575, Izmir, Turkey
| | - O G Calan
- Department of Biochemistry and Clinical Biochemistry, Dokuz Eylul University Faculty of Medicine, 35340, Inciralti, Izmir, Turkey
| |
Collapse
|
13
|
Calan M, Yilmaz O, Kume T, Unal Kocabas G, Yesil Senses P, Senses YM, Temur M, Gursoy Calan O. Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome. Endocrine 2016; 53:271-9. [PMID: 26832343 DOI: 10.1007/s12020-016-0875-z] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Accepted: 01/17/2016] [Indexed: 02/06/2023]
Abstract
Betatrophin is a newly identified hormone determined to be a potent inducer of pancreatic beta cell proliferation in response to insulin resistance in mice. Polycystic ovary syndrome (PCOS) is an inflammatory-based metabolic disease associated with insulin resistance. However, no evidence is available indicating whether betatrophin is involved in women with PCOS. The objective of this study was to ascertain whether betatrophin levels are altered in women with PCOS. This study was conducted in secondary referral center. This cross-sectional study included 164 women with PCOS and 164 age- and BMI-matched female controls. Circulating betatrophin levels were measured using ELISA. Metabolic and hormonal parameters were also determined. Circulating betatrophin levels were significantly elevated in women with PCOS compared with controls (367.09 ± 55.78 vs. 295.65 ± 48.97 pg/ml, P < 0.001). Betatrophin levels were positively correlated with insulin resistance marker homeostasis model assessment of insulin resistance (HOMA-IR), free-testosterone, high-sensitivity C-reactive protein (hs-CRP), atherogenic lipid profiles, and BMI in PCOS. Multivariate logistic regression analyses revealed that the odds ratio for PCOS was 2.51 for patients in the highest quartile of betatrophin compared with those in the lowest quartile (95 % CI 1.31-4.81, P = 0.006). Multivariate regression analyses showed that HOMA-IR, hs-CRP, and free-testosterone were independent factors influencing serum betatrophin levels. Betatrophin levels were increased in women with PCOS and were associated with insulin resistance, hs-CRP, and free-testosterone in these patients. Elevated betatrophin levels were found to increase the odds of having PCOS. Further research is needed to elucidate the physiologic and pathologic significance of our findings.
Collapse
Affiliation(s)
- Mehmet Calan
- Division of Endocrinology and Metabolism (PCOS Research Group), Department of Internal Medicine, Dokuz Eylul University Medical School, Inciralti, 35340, Izmir, Turkey.
| | - Ozgur Yilmaz
- Department of Obstetrics and Gynecology (PCOS Research Group), Manisa Merkezefendi State Hospital, Merkezefendi, 45020, Manisa, Turkey
| | - Tuncay Kume
- Department of Biochemistry and Clinical Biochemistry, Dokuz Eylul University Faculty of Medicine, Inciralti, 35340, Izmir, Turkey
| | - Gokcen Unal Kocabas
- Division of Endocrinology and Metabolism, Department of Internal Medicine (PCOS Research Group), Izmir Bozyaka Training and Research Hospital, Bozyaka, 35170, Izmir, Turkey
| | - Pinar Yesil Senses
- Department of Bioengineering, Ege University, Bornova, 35100, Izmir, Turkey
| | | | - Muzaffer Temur
- Department of Obstetrics and Gynecology (PCOS Research Group), Manisa Merkezefendi State Hospital, Merkezefendi, 45020, Manisa, Turkey
| | - Ozlem Gursoy Calan
- Department of Biochemistry and Clinical Biochemistry, Dokuz Eylul University Faculty of Medicine, Inciralti, 35340, Izmir, Turkey
| |
Collapse
|
14
|
Yurekli BS, Kutbay NO, Onay H, Simsir IY, Kocabas GU, Erdogan M, Cetinkalp S, Ozgen G, Saygili F. A novel CYP11B1 mutation in a Turkish patient with 11β-hydroxylase deficiency: An association with the severe hypokalemia leading to rhabdomyolysis. Hormones (Athens) 2016; 15:300-302. [PMID: 27376433 DOI: 10.14310/horm.2002.1654] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2015] [Accepted: 12/27/2015] [Indexed: 11/20/2022]
Affiliation(s)
- Banu Sarer Yurekli
- Endocrinology Department, Ege University Faculty of Medicine, Bornova, Izmir, Turkey.
| | | | - Huseyin Onay
- Endocrinology Department, Ege University Faculty of Medicine, Bornova, Izmir, Turkey
| | - Ilgin Yildirim Simsir
- Endocrinology Department, Ege University Faculty of Medicine, Bornova, Izmir, Turkey
| | - Gokcen Unal Kocabas
- Endocrinology Department, Ege University Faculty of Medicine, Bornova, Izmir, Turkey
| | - Mehmet Erdogan
- Endocrinology Department, Ege University Faculty of Medicine, Bornova, Izmir, Turkey
| | - Sevki Cetinkalp
- Endocrinology Department, Ege University Faculty of Medicine, Bornova, Izmir, Turkey
| | - Gokhan Ozgen
- Endocrinology Department, Ege University Faculty of Medicine, Bornova, Izmir, Turkey
| | - Fusun Saygili
- Endocrinology Department, Ege University Faculty of Medicine, Bornova, Izmir, Turkey
| |
Collapse
|
15
|
Saklamaz A, Calan M, Yilmaz O, Kume T, Temur M, Yildiz N, Kasap E, Genc M, Sarer Yurekli B, Unal Kocabas G. Polycystic ovary syndrome is associated with increased osteopontin levels. Eur J Endocrinol 2016; 174:415-23. [PMID: 26701868 DOI: 10.1530/eje-15-1074] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2015] [Accepted: 12/23/2015] [Indexed: 11/11/2022]
Abstract
OBJECTIVE Osteopontin (OPN) is a multi-functional secreted glycoprotein that plays a crucial role in glucose metabolism and inflammatory process. Growing evidence suggests that there is a link between OPN and ovarian function. However, no such link has yet been found for OPN in polycystic ovary syndrome (PCOS). Our aim was to ascertain whether circulating OPN levels are altered in women with PCOS and to determine whether OPN levels differ between the follicular phase and mid-cycle of the menstrual cycle in eumenorrheic women. DESIGN AND METHODS In total, 150 women with PCOS and 150 age- and BMI-matched controls without PCOS were recruited for this prospective observational study. OPN levels were measured using ELISA. Metabolic parameters were also determined. RESULTS Circulating OPN levels were significantly elevated in PCOS women compared with controls (69.12±31.59 ng/ml vs 42.66±21.28 ng/ml; P<0.001). OPN levels were significantly higher at mid-cycle than in the follicular phase in eumenorrheic women. OPN was positively correlated with BMI, homeostasis model assessment of insulin resistance (HOMA-IR), free testosterone, and high sensitivity C-reactive protein (hs-CRP). Multivariate logistic regression analyses revealed that the odds ratio (OR) for PCOS was 3.64 for patients in the highest quartile of OPN compared with those in the lowest quartile (OR=3.64; 95% CI=2.42-5.57; P=0.011). Our findings indicate that BMI, HOMA-IR, hs-CRP, and free testosterone are independent factors influencing serum OPN levels and that OPN is an independent predictor for HOMA-IR. CONCLUSION PCOS is associated with increased OPN levels.
Collapse
Affiliation(s)
| | - Mehmet Calan
- Division of Endocrinology and MetabolismDepartment of Internal Medicine, Sifa University School of Medicine, 35410 Izmir, TurkeyPCOS Research GroupDivision of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, 35170 Bozyaka, Izmir, TurkeyPCOS Research GroupDepartment of Obstetrics and Gynecology, Manisa Merkezefendi State Hospital, 45020 Merkezefendi, Manisa, TurkeyDepartment of Biochemistry and Clinical BiochemistryDokuz Eylul University Faculty of Medicine, 35340 Inciralti, Izmir, TurkeyDepartment of Obstetrics and GynecologySifa University School of Medicine, 35410 Izmir, TurkeyDivision of Endocrinology and MetabolismDepartment of Internal Medicine, Ege University Medical School, 35100 Bornova, Izmir, Turkey
| | - Ozgur Yilmaz
- Division of Endocrinology and MetabolismDepartment of Internal Medicine, Sifa University School of Medicine, 35410 Izmir, TurkeyPCOS Research GroupDivision of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, 35170 Bozyaka, Izmir, TurkeyPCOS Research GroupDepartment of Obstetrics and Gynecology, Manisa Merkezefendi State Hospital, 45020 Merkezefendi, Manisa, TurkeyDepartment of Biochemistry and Clinical BiochemistryDokuz Eylul University Faculty of Medicine, 35340 Inciralti, Izmir, TurkeyDepartment of Obstetrics and GynecologySifa University School of Medicine, 35410 Izmir, TurkeyDivision of Endocrinology and MetabolismDepartment of Internal Medicine, Ege University Medical School, 35100 Bornova, Izmir, Turkey
| | - Tuncay Kume
- Division of Endocrinology and MetabolismDepartment of Internal Medicine, Sifa University School of Medicine, 35410 Izmir, TurkeyPCOS Research GroupDivision of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, 35170 Bozyaka, Izmir, TurkeyPCOS Research GroupDepartment of Obstetrics and Gynecology, Manisa Merkezefendi State Hospital, 45020 Merkezefendi, Manisa, TurkeyDepartment of Biochemistry and Clinical BiochemistryDokuz Eylul University Faculty of Medicine, 35340 Inciralti, Izmir, TurkeyDepartment of Obstetrics and GynecologySifa University School of Medicine, 35410 Izmir, TurkeyDivision of Endocrinology and MetabolismDepartment of Internal Medicine, Ege University Medical School, 35100 Bornova, Izmir, Turkey
| | - Muzaffer Temur
- Division of Endocrinology and MetabolismDepartment of Internal Medicine, Sifa University School of Medicine, 35410 Izmir, TurkeyPCOS Research GroupDivision of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, 35170 Bozyaka, Izmir, TurkeyPCOS Research GroupDepartment of Obstetrics and Gynecology, Manisa Merkezefendi State Hospital, 45020 Merkezefendi, Manisa, TurkeyDepartment of Biochemistry and Clinical BiochemistryDokuz Eylul University Faculty of Medicine, 35340 Inciralti, Izmir, TurkeyDepartment of Obstetrics and GynecologySifa University School of Medicine, 35410 Izmir, TurkeyDivision of Endocrinology and MetabolismDepartment of Internal Medicine, Ege University Medical School, 35100 Bornova, Izmir, Turkey
| | - Nurdan Yildiz
- Division of Endocrinology and MetabolismDepartment of Internal Medicine, Sifa University School of Medicine, 35410 Izmir, TurkeyPCOS Research GroupDivision of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, 35170 Bozyaka, Izmir, TurkeyPCOS Research GroupDepartment of Obstetrics and Gynecology, Manisa Merkezefendi State Hospital, 45020 Merkezefendi, Manisa, TurkeyDepartment of Biochemistry and Clinical BiochemistryDokuz Eylul University Faculty of Medicine, 35340 Inciralti, Izmir, TurkeyDepartment of Obstetrics and GynecologySifa University School of Medicine, 35410 Izmir, TurkeyDivision of Endocrinology and MetabolismDepartment of Internal Medicine, Ege University Medical School, 35100 Bornova, Izmir, Turkey
| | - Esin Kasap
- Division of Endocrinology and MetabolismDepartment of Internal Medicine, Sifa University School of Medicine, 35410 Izmir, TurkeyPCOS Research GroupDivision of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, 35170 Bozyaka, Izmir, TurkeyPCOS Research GroupDepartment of Obstetrics and Gynecology, Manisa Merkezefendi State Hospital, 45020 Merkezefendi, Manisa, TurkeyDepartment of Biochemistry and Clinical BiochemistryDokuz Eylul University Faculty of Medicine, 35340 Inciralti, Izmir, TurkeyDepartment of Obstetrics and GynecologySifa University School of Medicine, 35410 Izmir, TurkeyDivision of Endocrinology and MetabolismDepartment of Internal Medicine, Ege University Medical School, 35100 Bornova, Izmir, Turkey
| | - Mine Genc
- Division of Endocrinology and MetabolismDepartment of Internal Medicine, Sifa University School of Medicine, 35410 Izmir, TurkeyPCOS Research GroupDivision of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, 35170 Bozyaka, Izmir, TurkeyPCOS Research GroupDepartment of Obstetrics and Gynecology, Manisa Merkezefendi State Hospital, 45020 Merkezefendi, Manisa, TurkeyDepartment of Biochemistry and Clinical BiochemistryDokuz Eylul University Faculty of Medicine, 35340 Inciralti, Izmir, TurkeyDepartment of Obstetrics and GynecologySifa University School of Medicine, 35410 Izmir, TurkeyDivision of Endocrinology and MetabolismDepartment of Internal Medicine, Ege University Medical School, 35100 Bornova, Izmir, Turkey
| | - Banu Sarer Yurekli
- Division of Endocrinology and MetabolismDepartment of Internal Medicine, Sifa University School of Medicine, 35410 Izmir, TurkeyPCOS Research GroupDivision of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, 35170 Bozyaka, Izmir, TurkeyPCOS Research GroupDepartment of Obstetrics and Gynecology, Manisa Merkezefendi State Hospital, 45020 Merkezefendi, Manisa, TurkeyDepartment of Biochemistry and Clinical BiochemistryDokuz Eylul University Faculty of Medicine, 35340 Inciralti, Izmir, TurkeyDepartment of Obstetrics and GynecologySifa University School of Medicine, 35410 Izmir, TurkeyDivision of Endocrinology and MetabolismDepartment of Internal Medicine, Ege University Medical School, 35100 Bornova, Izmir, Turkey
| | - Gokcen Unal Kocabas
- Division of Endocrinology and MetabolismDepartment of Internal Medicine, Sifa University School of Medicine, 35410 Izmir, TurkeyPCOS Research GroupDivision of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, 35170 Bozyaka, Izmir, TurkeyPCOS Research GroupDepartment of Obstetrics and Gynecology, Manisa Merkezefendi State Hospital, 45020 Merkezefendi, Manisa, TurkeyDepartment of Biochemistry and Clinical BiochemistryDokuz Eylul University Faculty of Medicine, 35340 Inciralti, Izmir, TurkeyDepartment of Obstetrics and GynecologySifa University School of Medicine, 35410 Izmir, TurkeyDivision of Endocrinology and MetabolismDepartment of Internal Medicine, Ege University Medical School, 35100 Bornova, Izmir, Turkey
| |
Collapse
|
16
|
Akyildiz ZI, Polat S, Yurekli BS, Kocabas GU, Tuluce K, Tuluce SY, Kocabas U, Bozkaya G, Yuksel A, Nazli C. Epicardial fat, body mass index, and triglyceride are independent contributors of serum fibroblast growth factor 21 level in obese premenopausal women. J Endocrinol Invest 2015; 38:361-6. [PMID: 25312836 DOI: 10.1007/s40618-014-0185-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Accepted: 09/29/2014] [Indexed: 12/24/2022]
Abstract
PURPOSE The hormone fibroblast growth factor 21 (FGF-21) regulates carbohydrate and lipid homeostasis. FGF-21 represents an attractive novel therapy for obesity since administration of FGF-21 has been shown to improve metabolic abnormalities in obese animal models. We investigated FGF-21 and its relationship with epicardial fat thickness (EFT), metabolic parameters, and inflammatory markers in premenopausal obese women compared to controls with similar Systematic Coronary Risk Evaluation (SCORE) project risk profiles. METHODS Forty-five obese premenopausal women with body mass index (BMI) ≥30 kg/m(2) and 41 control premenopausal women with BMI <25 kg/m(2) with similar SCORE project risk profiles were included in this case-control study. EFT was evaluated by two-dimensional transthoracic echocardiography. Serum FGF-21 was measured with an ELISA kit. RESULTS FGF-21 and EFT were significantly higher in obese women compared to controls (p < 0.001). Multiple stepwise linear regression analysis showed that EFT, BMI, and triglycerides (TG) independently contributed to FGF-21 (R(2) = 0.757, p < 0.001). However, homeostasis model assessment of insulin resistance (HOMA-IR), visceral ectopic fat, and inflammatory markers were not found as a direct contributor to serum FGF-21 level (p > 0.05). CONCLUSIONS EFT, BMI, and TG may play an important role in predicting serum FGF-21 level which may be a potential therapeutic target in cardiometabolic disorders in the future.
Collapse
Affiliation(s)
- Z I Akyildiz
- Department of Cardiology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Basin Sitesi, 35360, Izmir, Turkey.
| | - S Polat
- Department of Internal Medicine, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
| | - B S Yurekli
- Department of Endocrinology and Metabolism, Ege University Faculty of Medicine, Izmir, Turkey
| | - G U Kocabas
- Department of Endocrinology, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
| | - K Tuluce
- Department of Cardiology, Izmir Karsiyaka State Hospital, Izmir, Turkey
| | - S Y Tuluce
- Department of Cardiology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Basin Sitesi, 35360, Izmir, Turkey
| | - U Kocabas
- Department of Cardiology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Basin Sitesi, 35360, Izmir, Turkey
| | - G Bozkaya
- Department of Biochemistry, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
| | - A Yuksel
- Department of Internal Medicine, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
| | - C Nazli
- Department of Cardiology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Basin Sitesi, 35360, Izmir, Turkey
| |
Collapse
|
17
|
Abstract
A 34-year-old female presented to our clinic with a 1.5 year history of secondary amenorrhea and galactorrhea. Prolactin (PRL) level was found to be 151.89 ng/ml. Pituitary imaging was reported to be normal. An examination of the patient revealed that PRL level was still high so the dose of cabergoline was further increased and subsequently, bromocriptine was added to the treatment. There was no reduction in PRL levels in controls. A scanning was performed to look for an ectopic focus. Abdominal computerized tomography revealed a heterogenous mass lesion originating from the uterus. Octreotide scintigraphy was performed and we observed an involvement consistent with the mass in the uterus. The patient underwent abdominal total hysterectomy. PRL dropped to 0.4 ng/ml the next day after the operation. The pathology result was a low-grade malignant mesenchymal tumor. Prolactin was found to be immunohistochemically negative. However, galactorrhea disappeared postoperative and PRL levels are still low. Elevated levels of PRL, resistant to bromocriptine and cabergoline, rapidly returned to normal after hysterectomy, which obviously indicates that hyperprolactinemia was associated with the myoma of the uterus.
Collapse
Affiliation(s)
- Ilgin Yildirim Simsir
- Ege University Medical Faculty, Deparment of Internal Medicine, Division of Endocrinology and Metabolism, Izmir, Turkey.
| | | | | | | | | | | | | | | |
Collapse
|